OncoPredictor combines MDS Pharma Services OncoPanel with Compendia Bioscience’s Oncomine for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.
MDS Pharma Services OncoPanel service provides high content screening of up to 240 cancer cell lines to assess the cytotoxicity and chemotherapeutic potential of specific cancer drugs and drug combinations.
Compendia’s Oncomine, a database of cancer genomic profiles coupled with an analysis web application, provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from more than 27,000 reference patients based on molecular, pathological and histological sub-types.
Through this collaboration, the OncoPredictor system will enable the analysis of drug sensitivity and resistance of novel drugs and drug combinations as well as the identification of associations with both disease sub-types and underlying tumor biology, the two companies said.
Dan Rhodes, CEO and co-founder of Compendia, said: “Based on our experience working with 15 of the top 20 companies pursuing the development of cancer treatments, we believe this integrated solution could revolutionize cancer genomics for drug development. OncoPredictor provides the right experimental scale, in terms of cell line data and reference patient data, to deliver the answers our customers are seeking.”